Hepatitis Vaccine

Pre and Post Immunization measures

Despite the challenges in studying hepatitis, considerable progress has been in made in characterizing anti-hepatitis immune responses. It has been estimated that approximately 20% of individuals are able to clear the infection spontaneously following acute Hepatitis infection, whereas the rest progresses to chronicity. Longitudinal studies of the two cohorts of patients during and after acute infection have defined immunologic correlates that are associated with viral clearance.

A strong T-cell response, characterized by the production of effector cytokines including IFN-γ, and broad epitope specifically correlate with the resolution of acute infection. After clearance of the acute infection, memory T cells are maintained, but whether they can provide protection against reinfection is incompletely understood. While usually not resulting in sterilizing immunity, that is, prevention of acute infection after re-exposure especially to antigenically more divergent hepatitis strains, adaptive immunity protects against progression to chronic infection following repeated hepatitis exposure. As chronic infection persists, the number of epitopes recognized decreases and T-cell responses are often lost. Since hepatitis-associated morbidity and mortality are caused by chronic infection, a vaccine, even if it only prevents viral persistence, would greatly ameliorate the problem. Although neutralizing antibodies are present during the chronic phase of infection, these antibodies are not able to clear the virus. Several mechanisms of viral escape from antibody-mediated neutralization have been postulated and tested. Recently, several human monoclonal antibodies against hepatitis envelope protein E1 or E2, which show cross neutralizing capability, were identified. These antibodies were able to prevent infection of heterologous hepatitis in the hepatitis pseudo particle and hepatitis cell culture model system, suggesting passive prophylaxis with exogenous neutralizing antibodies or eliciting high-affinity antibodies with similar specificity representing a viable strategy to prevent or more efficiently control hepatitis infections.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA
• 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, Nov 10-12, 2016, Australia
• 10th Euro Global Summit and Expo on Vaccines & Vaccination, June 16-18, 2016, Italy
• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 11^th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada
• The Viral Hepatitis Congress, Germany
• The Singapore Hepatitis Conference, Singapore